BRPI0207961B8 - uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. - Google Patents

uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.

Info

Publication number
BRPI0207961B8
BRPI0207961B8 BRPI0207961A BRPI0207961B8 BR PI0207961 B8 BRPI0207961 B8 BR PI0207961B8 BR PI0207961 A BRPI0207961 A BR PI0207961A BR PI0207961 B8 BRPI0207961 B8 BR PI0207961B8
Authority
BR
Brazil
Prior art keywords
epothilone
kit
compounds
cancerous tumors
treat solid
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Y F Lee Francis
Original Assignee
Bristol Myers Squibb Co
R Pharm Us Operating Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, R Pharm Us Operating Llc filed Critical Bristol Myers Squibb Co
Publication of BR0207961A publication Critical patent/BR0207961A/pt
Publication of BRPI0207961A8 publication Critical patent/BRPI0207961A8/pt
Publication of BRPI0207961B1 publication Critical patent/BRPI0207961B1/pt
Publication of BRPI0207961B8 publication Critical patent/BRPI0207961B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0207961 2001-03-14 2002-03-05 uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. BRPI0207961B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27580101P 2001-03-14 2001-03-14
US31639501P 2001-08-31 2001-08-31
PCT/US2002/006746 WO2002072085A1 (en) 2001-03-14 2002-03-05 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases

Publications (4)

Publication Number Publication Date
BR0207961A BR0207961A (pt) 2004-04-20
BRPI0207961A8 BRPI0207961A8 (pt) 2017-09-19
BRPI0207961B1 BRPI0207961B1 (pt) 2019-11-19
BRPI0207961B8 true BRPI0207961B8 (pt) 2021-05-25

Family

ID=29254237

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0207961 BRPI0207961B8 (pt) 2001-03-14 2002-03-05 uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.

Country Status (25)

Country Link
US (5) US7312237B2 (enExample)
EP (1) EP1383490B1 (enExample)
JP (1) JP2004529904A (enExample)
KR (1) KR20040025904A (enExample)
CN (1) CN1496256A (enExample)
AT (1) ATE554756T1 (enExample)
AU (1) AU2002248542B9 (enExample)
BG (1) BG66289B1 (enExample)
BR (1) BRPI0207961B8 (enExample)
CA (1) CA2440555A1 (enExample)
CZ (1) CZ305799B6 (enExample)
EE (1) EE05417B1 (enExample)
ES (1) ES2384789T3 (enExample)
HR (1) HRP20030831B1 (enExample)
HU (1) HU230273B1 (enExample)
IL (2) IL157443A0 (enExample)
IS (1) IS2882B (enExample)
MX (1) MXPA03008135A (enExample)
NO (1) NO333972B1 (enExample)
PL (1) PL368973A1 (enExample)
RU (1) RU2321400C2 (enExample)
SK (1) SK11082003A3 (enExample)
TW (1) TWI330530B (enExample)
WO (1) WO2002072085A1 (enExample)
ZA (1) ZA200307123B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
CA2438610A1 (en) 2001-02-20 2002-08-29 Francis Y. F. Lee Treatment of refractory tumors using epothilone derivatives
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
EE200400074A (et) * 2001-08-31 2004-06-15 Bristol-Myers Squibb Company Koostised ning nende kasutamine proliferatiivsetehaiguste raviks
TWI341728B (en) * 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
PL372070A1 (en) * 2002-06-10 2005-07-11 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US7008936B2 (en) * 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CA2496477C (en) * 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP2006504745A (ja) * 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド エポｄ及び５−ｆｕ／ゲムシタビン
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
MXPA06002393A (es) * 2003-09-02 2006-06-20 Novartis Ag Tratamiento de cancer con epotilomas.
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
CA2573949A1 (en) * 2004-07-26 2006-02-02 Novartis Ag Epothilone combinations
CA2588400A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising ixabepilone, and preparation thereof
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US20070190544A1 (en) * 2005-10-28 2007-08-16 Emory University Methods of screening for resistance to microtuble-targeting drugs
US20110104664A1 (en) 2006-03-31 2011-05-05 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
EP2004184A2 (en) * 2006-04-05 2008-12-24 Novartis AG Combinations of therapeutic agents for treating cancer
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
CN101732310B (zh) * 2006-07-12 2011-07-20 湖南迪诺制药有限公司 埃博霉素b的用途
CN101909693A (zh) * 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2010057006A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
US8435972B2 (en) * 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
EP4087545A1 (en) 2020-01-10 2022-11-16 R-Pharm US Operating LLC Compositions of ixabepilone
TW202326134A (zh) * 2021-12-24 2023-07-01 國立清華大學 用於破壞細胞內微管的方法及平台

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247942A (en) * 1961-03-01 1981-01-27 Ford Aerospace & Communications Corp. Jam resistant communication system
CH513157A (de) * 1967-02-27 1971-09-30 Hoffmann La Roche Verfahren zur Herstellung von Pyrrolinverbindungen
US3831013A (en) * 1973-02-20 1974-08-20 Us Navy Correlators using shift registers
US3900721A (en) * 1974-02-14 1975-08-19 Us Navy Serial-access linear transform
US4653069A (en) * 1975-11-06 1987-03-24 General Electric Company Spread spectrum correlation receiver
US4112372A (en) * 1977-01-11 1978-09-05 Texas Instruments Incorporated Spread spectrum communication system
US4285060A (en) * 1978-02-28 1981-08-18 Harris Corporation Spread spectrum code tracking loop
US4222115A (en) * 1978-03-13 1980-09-09 Purdue Research Foundation Spread spectrum apparatus for cellular mobile communication systems
US4193031A (en) * 1978-03-13 1980-03-11 Purdue Research Foundation Method of signal transmission and reception utilizing wideband signals
US4189677A (en) * 1978-03-13 1980-02-19 Purdue Research Foundation Demodulator unit for spread spectrum apparatus utilized in a cellular mobile communication system
DE3023375C1 (enExample) * 1980-06-23 1987-12-03 Siemens Ag, 1000 Berlin Und 8000 Muenchen, De
US4455651A (en) * 1980-10-20 1984-06-19 Equatorial Communications Company Satellite communications system and apparatus
US4730340A (en) * 1980-10-31 1988-03-08 Harris Corp. Programmable time invariant coherent spread symbol correlator
US4392232A (en) * 1981-09-28 1983-07-05 B-Systems, Inc. Simplified transversal correlator for MSK and MSK related waveforms
US4425642A (en) * 1982-01-08 1984-01-10 Applied Spectrum Technologies, Inc. Simultaneous transmission of two information signals within a band-limited communications channel
US4479226A (en) * 1982-03-29 1984-10-23 At&T Bell Laboratories Frequency-hopped single sideband mobile radio system
US4563774A (en) * 1982-10-25 1986-01-07 At&T Bell Laboratories Address coded communication system
US4755983A (en) * 1983-03-01 1988-07-05 Hazeltine Corporation Dedicated message matched filter
US4512013A (en) * 1983-04-11 1985-04-16 At&T Bell Laboratories Simultaneous transmission of speech and data over an analog channel
US4523311A (en) * 1983-04-11 1985-06-11 At&T Bell Laboratories Simultaneous transmission of speech and data over an analog channel
US4538280A (en) * 1983-05-05 1985-08-27 E-Systems, Inc. Coherent spread spectrum pseudonoise tracking loop
FR2549663A1 (fr) * 1983-07-21 1985-01-25 Snecma Procede et dispositif pour le codage et le decodage d'une emission a large bande
GB2144310A (en) * 1983-08-01 1985-02-27 Philips Electronic Associated Multiple-access communications system
US4649549A (en) * 1983-08-30 1987-03-10 Sophisticated Signals And Circuits Apparatus for synchronizing linear PN sequences
US4641322A (en) * 1983-10-18 1987-02-03 Nec Corporation System for carrying out spread spectrum communication through an electric power line
JPS60103834A (ja) * 1983-11-11 1985-06-08 Nippo Tsushin Kogyo Kk 個人呼出通信システム
US4660164A (en) * 1983-12-05 1987-04-21 The United States Of America As Represented By The Secretary Of The Navy Multiplexed digital correlator
US4672605A (en) * 1984-03-20 1987-06-09 Applied Spectrum Technologies, Inc. Data and voice communications system
JPS60220635A (ja) * 1984-04-17 1985-11-05 Clarion Co Ltd スペクトラム拡散送受信機
DE3427058A1 (de) * 1984-07-23 1986-02-06 Standard Elektrik Lorenz Ag, 7000 Stuttgart Empfaenger fuer bandgespreizte signale
US4639914A (en) * 1984-12-06 1987-01-27 At&T Bell Laboratories Wireless PBX/LAN system with optimum combining
DE3447107A1 (de) * 1984-12-22 1986-06-26 Philips Patentverwaltung Gmbh, 2000 Hamburg Verfahren zur nachrichtenuebertragung in einem digitalen funkuebertragungssystem
GB2171576B (en) * 1985-02-04 1989-07-12 Mitel Telecom Ltd Spread spectrum leaky feeder communication system
US4675839A (en) * 1985-04-10 1987-06-23 Allied Corporation Receiver for a spread spectrum communication system having a time-multiplexed convolver
CA1259430A (en) * 1985-07-19 1989-09-12 Fumio Akashi Multipoint communication system having polling and reservation schemes
US4672658A (en) * 1985-10-16 1987-06-09 At&T Company And At&T Bell Laboratories Spread spectrum wireless PBX
US4647863A (en) * 1985-11-01 1987-03-03 The United States Of America As Represented By The Secretary Of The Army Saw transition detector for PSK signals
US4718080A (en) * 1985-12-16 1988-01-05 Serrano Arthur L Microprocessor controlled interface for cellular system
US4703474A (en) * 1986-02-28 1987-10-27 American Telephone And Telegraph Company, At&T Bell Laboratories Spread spectrum code-division-multiple-access (SS-CDMA) lightwave communication system
FR2595889B1 (fr) * 1986-03-14 1988-05-06 Havel Christophe Dispositif de controle de puissance d'emission dans une station emettrice-receptrice de radiocommunication
JPS6374330A (ja) * 1986-09-18 1988-04-04 Sony Corp 無線通信方法及びそれに用いる通信機
JPS6397033A (ja) * 1986-10-14 1988-04-27 Kenwood Corp スペクトラム拡散通信方式における同期パルス発生回路
US4901307A (en) * 1986-10-17 1990-02-13 Qualcomm, Inc. Spread spectrum multiple access communication system using satellite or terrestrial repeaters
US4759034A (en) * 1986-12-02 1988-07-19 General Research Of Electronics, Inc. Multi-step spread spectrum communication apparatus
US4775995A (en) * 1986-12-22 1988-10-04 Motorola, Inc. Adaptive splatter control
US4932037A (en) * 1987-02-11 1990-06-05 Hillier Technologies Limited Partnership Remote control system, components and methods
JP2624964B2 (ja) * 1987-06-09 1997-06-25 キヤノン株式会社 無線通信装置
US4799253A (en) * 1987-07-20 1989-01-17 Motorola, Inc. Colocated cellular radiotelephone systems
US4899364A (en) * 1987-07-31 1990-02-06 Clarion Co., Ltd. Automatic gain control system
US4850036A (en) * 1987-08-21 1989-07-18 American Telephone And Telegraph Company Radio communication system using synchronous frequency hopping transmissions
US4894842A (en) * 1987-10-15 1990-01-16 The Charles Stark Draper Laboratory, Inc. Precorrelation digital spread spectrum receiver
US4922506A (en) * 1988-01-11 1990-05-01 Sicom Corporation Compensating for distortion in a communication channel
US4805208A (en) * 1988-01-15 1989-02-14 Niravoice, Inc. Modem compression system for telephone network
US4914651A (en) * 1988-09-20 1990-04-03 Cellular Data, Inc. Cellular data system
EP0369923B1 (fr) * 1988-11-15 1993-09-15 José Vidal Sans Dipositif obturateur pour le contrôle d'iléo-colostomies
US4930140A (en) * 1989-01-13 1990-05-29 Agilis Corporation Code division multiplex system using selectable length spreading code sequences
JPH07120968B2 (ja) * 1989-02-07 1995-12-20 クラリオン株式会社 スペクトラム拡散通信装置
JP2718978B2 (ja) * 1989-03-02 1998-02-25 株式会社トキメック データ伝送方式
US4991164A (en) * 1989-03-23 1991-02-05 Telettra-Telefonia Elettronica E Radio S.P.A. Automatic transmit power level control in radio links
US4993021A (en) * 1989-03-23 1991-02-12 Telettra-Telefonia Elettronica E Radio Spa Automatic transmit power level control in radio links
JP2769478B2 (ja) * 1989-04-10 1998-06-25 三菱電機株式会社 無線機
JP2720076B2 (ja) * 1989-07-17 1998-02-25 京セラ株式会社 直接スペクトラム拡散受信機の自動校正装置
US5016255A (en) * 1989-08-07 1991-05-14 Omnipoint Data Company, Incorporated Asymmetric spread spectrum correlator
US5022047A (en) * 1989-08-07 1991-06-04 Omnipoint Data Corporation Spread spectrum correlator
US5016256A (en) * 1989-10-17 1991-05-14 Stewart Clarence H Spread spectrum intercept apparatus and method
US5101501A (en) * 1989-11-07 1992-03-31 Qualcomm Incorporated Method and system for providing a soft handoff in communications in a cdma cellular telephone system
US5257283A (en) * 1989-11-07 1993-10-26 Qualcomm Incorporated Spread spectrum transmitter power control method and system
US5109390A (en) * 1989-11-07 1992-04-28 Qualcomm Incorporated Diversity receiver in a cdma cellular telephone system
US5056109A (en) * 1989-11-07 1991-10-08 Qualcomm, Inc. Method and apparatus for controlling transmission power in a cdma cellular mobile telephone system
US5005169A (en) * 1989-11-16 1991-04-02 Westinghouse Electric Corp. Frequency division multiplex guardband communication system for sending information over the guardbands
US5073900A (en) * 1990-03-19 1991-12-17 Mallinckrodt Albert J Integrated cellular communications system
JP2748656B2 (ja) * 1990-06-19 1998-05-13 ソニー株式会社 移動無線通信方法
US5103459B1 (en) * 1990-06-25 1999-07-06 Qualcomm Inc System and method for generating signal waveforms in a cdma cellular telephone system
US5040238A (en) * 1990-06-29 1991-08-13 Motorola, Inc. Trunking system communication resource reuse method
US5129098A (en) * 1990-09-24 1992-07-07 Novatel Communication Ltd. Radio telephone using received signal strength in controlling transmission power
US5093840A (en) * 1990-11-16 1992-03-03 Scs Mobilecom, Inc. Adaptive power control for a spread spectrum transmitter
US5299226A (en) * 1990-11-16 1994-03-29 Interdigital Technology Corporation Adaptive power control for a spread spectrum communications system and method
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5396516A (en) * 1993-02-22 1995-03-07 Qualcomm Incorporated Method and system for the dynamic modification of control paremeters in a transmitter power control system
US6441026B1 (en) 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
JP4183099B2 (ja) 1995-11-17 2008-11-19 ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃおよびｄ、製造法ならびに組成物
US5758687A (en) * 1996-05-13 1998-06-02 Funicello; John C. Dual arm overhead air supply system
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
WO1998022461A1 (de) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
NZ337195A (en) 1997-02-25 2001-05-25 Biotechnolog Forschung Gmbh Epothilones with a modified side chain
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ATE224882T1 (de) 1997-07-16 2002-10-15 Schering Ag Thiazolderivate, verfahren zur herstellung und verwendung
DK1005465T3 (da) 1997-08-09 2007-11-05 Bayer Schering Pharma Ag Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
KR20080016756A (ko) 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
KR100716272B1 (ko) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
ES2207983T3 (es) 1998-12-22 2004-06-01 Novartis Ag Derivados de epotilona y su uso como agentes antitumorales.
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
CA2356462A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030191162A1 (en) 1998-12-31 2003-10-09 Sugen Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
MXPA01006742A (es) 1998-12-31 2004-04-21 Sugen Inc Compuestos 3-heteroarilidenil-2-indolinona para modular la actividad de la quinasa de proteina y para utilizarse en la quimioterapia de cancer.
NZ513268A (en) 1999-02-18 2004-05-28 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US6262094B1 (en) * 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
GB9909925D0 (en) 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
EP1198251B1 (en) 1999-07-23 2006-11-29 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent
WO2001034133A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
DE60030164T2 (de) 1999-12-30 2007-08-30 Sugen, Inc., San Francisco 3-Heteroarylidenyl-2-Indolinon Derivate für die Modulierung der Aktivität einer Proteinkinase und für die Verwendung bei der Chemotherapie von Krebs
US6280395B1 (en) * 2000-01-19 2001-08-28 Mpr Health Systems, Inc. System and method for determining muscle dysfunction
WO2001064650A2 (en) * 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Center Synthesis of epothilones, intermediates thereto and analogues thereof
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US6462017B1 (en) 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AR033680A1 (es) 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
AU2002234165A1 (en) 2000-11-03 2002-05-27 Tularik, Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
EP1419137A2 (de) 2001-01-18 2004-05-19 Cognis Deutschland GmbH & Co. KG Verfahren zur herstellung von acylaminosäuren
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
JP2004521122A (ja) 2001-01-25 2004-07-15 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン類似体の非経口製剤
BRPI0206509B8 (pt) 2001-01-25 2021-05-25 R Pharm Us Operating Llc processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
MXPA03007423A (es) 2001-02-20 2003-11-18 Bristol Myers Squibb Co Derivados de epotilona para tratamiento de tumores refractarios.
CA2438610A1 (en) 2001-02-20 2002-08-29 Francis Y. F. Lee Treatment of refractory tumors using epothilone derivatives
CN1511036B (zh) 2001-02-27 2010-05-05 诺瓦提斯公司 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
JP2004519493A (ja) 2001-03-19 2004-07-02 ノバルティス アクチエンゲゼルシャフト 抗下痢剤およびエポチロンまたはエポチロン誘導体を含む組合せ剤
DE60215793T2 (de) 2001-05-03 2007-09-06 F. Hoffmann-La Roche Ag Kombination eines gelatinasehemmers und eines anti-tumor-agent, und deren verwendung
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI341728B (en) 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites

Also Published As

Publication number Publication date
US20050159461A1 (en) 2005-07-21
AU2002248542B2 (en) 2007-01-18
EE05417B1 (et) 2011-06-15
NO20034056D0 (no) 2003-09-12
HRP20030831B1 (en) 2012-08-31
BG66289B1 (en) 2013-02-28
AU2002248542B9 (en) 2007-04-26
NO333972B1 (no) 2013-11-04
PL368973A1 (en) 2005-04-04
US20100015149A1 (en) 2010-01-21
CZ20032376A3 (cs) 2004-09-15
US7312237B2 (en) 2007-12-25
HUP0400203A3 (en) 2006-02-28
BR0207961A (pt) 2004-04-20
HRP20030831A2 (en) 2004-08-31
EP1383490A1 (en) 2004-01-28
EE200300440A (et) 2003-12-15
KR20040025904A (ko) 2004-03-26
IS6950A (is) 2003-09-12
EP1383490A4 (en) 2009-03-18
RU2321400C2 (ru) 2008-04-10
WO2002072085A1 (en) 2002-09-19
HU230273B1 (hu) 2015-11-30
CA2440555A1 (en) 2002-09-19
CN1496256A (zh) 2004-05-12
CZ305799B6 (cs) 2016-03-23
SK11082003A3 (sk) 2004-08-03
US20040214871A1 (en) 2004-10-28
US8569347B2 (en) 2013-10-29
BRPI0207961B1 (pt) 2019-11-19
EP1383490B1 (en) 2012-04-25
BRPI0207961A8 (pt) 2017-09-19
IL157443A0 (en) 2004-03-28
BG108137A (en) 2005-01-31
NO20034056L (no) 2003-11-05
US20110033457A1 (en) 2011-02-10
TWI330530B (en) 2010-09-21
JP2004529904A (ja) 2004-09-30
IL157443A (en) 2011-12-29
MXPA03008135A (es) 2003-12-12
IS2882B (is) 2014-05-15
RU2003130377A (ru) 2005-03-10
US8598215B2 (en) 2013-12-03
US20030073677A1 (en) 2003-04-17
ATE554756T1 (de) 2012-05-15
HK1060843A1 (en) 2004-08-27
HUP0400203A2 (hu) 2004-08-30
ZA200307123B (en) 2005-02-23
ES2384789T3 (es) 2012-07-12

Similar Documents

Publication Publication Date Title
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
WO2004093803A3 (en) Photochemotherapeutic compounds for use in treatment of pin1-associated states
PA8537501A1 (es) Naftostirilos
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
DE60014873D1 (de) Synergistische zusammensetzungen zur krebsbehandlung
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
AR012626A1 (es) Una composicion farmaeutica que comprende un derivado o análogo de leptina como inhibidor de la proliferacion de células de tumor y el uso de dicha composicion farmaceutica para la manufactura de medicamento para el tratamiento de tumores
EA200200922A1 (ru) Композиция, включающая камптотецин и производное пиримидина, для лечения рака
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
ES2097905T3 (es) Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres.
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
HUP0302913A3 (en) Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
BRPI0413439A (pt) combinações compreendendo estaurosporinas
BR0302590A (pt) Agente para tratamento de tumores sólidos
NO20033341D0 (no) Metoder for administrering av epothilone-analoger for behandling av kreft
BR0111785A (pt) Composições e métodos para tratamento de candidìase
EE200300057A (et) Koostis vähi profülaktikaks ja raviks

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/335; A61P 1/18, 11/00, 13/08, 13/10, 35/00, 35/02, 35/04, 43/00, 1/00, 13/00

Ipc: A61K 31/335 (2011.01), A61P 1/18 (2011.01), A61P 1

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: R-PHARM US OPERATING, LLC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/03/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2712 DE 27-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.